TY - JOUR
T1 - Differential regulation of oxidative stress and cytokine production by endothelin ETA and ETB receptors in superoxide anion-induced inflammation and pain in mice
AU - Fattori, Victor
AU - Serafim, Karla G.G.
AU - Zarpelon, Ana C.
AU - Borghi, Sergio M.
AU - Pinho-Ribeiro, Felipe A.
AU - Alves-Filho, José C.
AU - Cunha, Thiago M.
AU - Cunha, Fernando Q.
AU - Casagrande, Rúbia
AU - Verri, Waldiceu A.
N1 - Funding Information:
Conselho Nacional de Desenvolvimento Científico e Tecnológico, 10.13039/501100003593, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, 10.13039/501100002322, Fundaçãao Araucária, 10.13039/501100004612, Fundação de Amparo à Pesquisa do Estado de São Paulo, 10.13039/501100001807 [2011/ 19670-0 (Thematic Project), 2013/08216-2 (Center for Research in Inflammatory Diseases)].
Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/3/16
Y1 - 2017/3/16
N2 - The present study investigated whether endothelin-1 acts via ETA or ETB receptors to mediate superoxide anion-induced pain and inflammation. Mice were treated with clazosentan (ETA receptor antagonist) or BQ-788 (ETB receptor antagonist) prior to stimulation with the superoxide anion donor, KO2. Intraplantar treatment with 30 nmol of clazosentan or BQ-788 reduced mechanical hyperalgesia (47% and 42%), thermal hyperalgesia (68% and 76%), oedema (50% and 30%); myeloperoxidase activity (64% and 32%), and overt-pain like behaviours, such as paw flinching (42% and 42%) and paw licking (38% and 62%), respectively. Similarly, intraperitoneal treatment with 30 nmol of clazosentan or BQ-788 reduced leukocyte recruitment to the peritoneal cavity (58% and 32%) and abdominal writhing (81% and 77%), respectively. Additionally, intraplantar treatment with clazosentan or BQ-788 decreased spinal (45% and 41%) and peripheral (47% and 47%) superoxide anion production as well as spinal (47% and 47%) and peripheral (33% and 54%) lipid peroxidation, respectively. Intraplantar treatment with clazosentan, but not BQ-788, reduced spinal (71%) and peripheral (51%) interleukin-1 beta as well as spinal (59%) and peripheral (50%) tumor necrosis factor-alpha production. Therefore, the present study unveils the differential mechanisms by which ET-1, acting on ETA or ETB receptors, regulates superoxide anion-induced inflammation and pain.
AB - The present study investigated whether endothelin-1 acts via ETA or ETB receptors to mediate superoxide anion-induced pain and inflammation. Mice were treated with clazosentan (ETA receptor antagonist) or BQ-788 (ETB receptor antagonist) prior to stimulation with the superoxide anion donor, KO2. Intraplantar treatment with 30 nmol of clazosentan or BQ-788 reduced mechanical hyperalgesia (47% and 42%), thermal hyperalgesia (68% and 76%), oedema (50% and 30%); myeloperoxidase activity (64% and 32%), and overt-pain like behaviours, such as paw flinching (42% and 42%) and paw licking (38% and 62%), respectively. Similarly, intraperitoneal treatment with 30 nmol of clazosentan or BQ-788 reduced leukocyte recruitment to the peritoneal cavity (58% and 32%) and abdominal writhing (81% and 77%), respectively. Additionally, intraplantar treatment with clazosentan or BQ-788 decreased spinal (45% and 41%) and peripheral (47% and 47%) superoxide anion production as well as spinal (47% and 47%) and peripheral (33% and 54%) lipid peroxidation, respectively. Intraplantar treatment with clazosentan, but not BQ-788, reduced spinal (71%) and peripheral (51%) interleukin-1 beta as well as spinal (59%) and peripheral (50%) tumor necrosis factor-alpha production. Therefore, the present study unveils the differential mechanisms by which ET-1, acting on ETA or ETB receptors, regulates superoxide anion-induced inflammation and pain.
KW - BQ-788
KW - clazosentan
KW - hyperalgesia
KW - interleukin-1β
KW - leukocyte recruitment
KW - lipid peroxidation
KW - nitric oxide
KW - nociception
KW - oedema
KW - tumor necrosis factor-α
UR - http://www.scopus.com/inward/record.url?scp=84992187799&partnerID=8YFLogxK
U2 - 10.1080/1061186X.2016.1245308
DO - 10.1080/1061186X.2016.1245308
M3 - Article
C2 - 27701898
AN - SCOPUS:84992187799
SN - 1061-186X
VL - 25
SP - 264
EP - 274
JO - Journal of Drug Targeting
JF - Journal of Drug Targeting
IS - 3
ER -